Frazier Management’s Cardiff Oncology CRDF Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-293,500
Closed -$2.72M 36
2021
Q1
$2.72M Sell
293,500
-275,000
-48% -$3.34M 0.22% 32
2020
Q4
$10.2M Buy
568,500
+308,500
+119% +$5.42M 0.79% 21
2020
Q3
$3.69M Buy
+260,000
New +$1.72M 0.33% 23

Other funds holding CRDF

Frazier Management's CRDF Position: Q2 2021 in Review

Frazier Management sold out of Cardiff Oncology (CRDF) in Q2 2021, closing a stake of 293,500 shares — an estimated $2.72M sold.

Frazier Management first reported a position in CRDF in Q3 2020 and held it in 3 quarters. The position peaked at $10.2M in Q4 2020. 90 funds tracked by Wall St. Rank hold CRDF as of Q2 2021.

  • Frazier Management reported no remaining Cardiff Oncology position as of Q2 2021 after selling out during the quarter.
  • Frazier Management sold 293,500 Cardiff Oncology shares in Q2 2021, an estimated $2.72M.
  • Frazier Management first reported a position in Cardiff Oncology in Q3 2020 and held it in 3 quarters.
  • Frazier Management's Cardiff Oncology position peaked at $10.2M in Q4 2020.
  • 90 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2021.

Based on Frazier Management's 13F filing for Q2 2021, filed 11 Aug 2021.